Paper41594255
Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response.
Canillas L and 8 others. Diagnostics (Basel), 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response. Papers, record 41594255. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41594255
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35120736 | Baveno VII - Renewing consensus in portal hypertension. | J Hepatol | 2022 | https://conductscience.org/library/papers/35120736 | PubMed |
| 2 | 31493238 | Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. | J Gastroenterol | 2020 | https://conductscience.org/library/papers/31493238 | PubMed |
| 3 | 19243014 | Liver biopsy. | Hepatology | 2009 | https://conductscience.org/library/papers/19243014 | PubMed |
| 4 | 38521170 | Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure. | J Hepatol | 2024 | https://conductscience.org/library/papers/38521170 | PubMed |
| 5 | 33529675 | Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. | Gastroenterology | 2021 | https://conductscience.org/library/papers/33529675 | PubMed |
| 6 | 38845253 | EASL position paper on clinical follow-up after HCV cure. | J Hepatol | 2024 | https://conductscience.org/library/papers/38845253 | PubMed |
| 7 | 30141222 | Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection. | J Viral Hepat | 2019 | https://conductscience.org/library/papers/30141222 | PubMed |
| 8 | 31629779 | Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. | J Hepatol | 2020 | https://conductscience.org/library/papers/31629779 | PubMed |
| 9 | 32956768 | EASL recommendations on treatment of hepatitis C: Final update of the series☆. | J Hepatol | 2020 | https://conductscience.org/library/papers/32956768 | PubMed |
| 10 | 29235144 | Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents. | Histopathology | 2018 | https://conductscience.org/library/papers/29235144 | PubMed |
| 11 | 33022803 | A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. | Hepatology | 2020 | https://conductscience.org/library/papers/33022803 | PubMed |
| 12 | 21354227 | Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. | J Hepatol | 2011 | https://conductscience.org/library/papers/21354227 | PubMed |
| 13 | 26918878 | Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation. | Histopathology | 2016 | https://conductscience.org/library/papers/26918878 | PubMed |
| 14 | 34525253 | Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease. | Liver Int | 2021 | https://conductscience.org/library/papers/34525253 | PubMed |
| 15 | 40532848 | Metabolic factors drive early increase in hepatic steatosis despite improvement in non-invasive fibrosis markers after hepatitis C eradication with direct-acting antivirals. | Clin Res Hepatol Gastroenterol | 2025 | https://conductscience.org/library/papers/40532848 | PubMed |
| 16 | 27910154 | Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. | Aliment Pharmacol Ther | 2017 | https://conductscience.org/library/papers/27910154 | PubMed |
| 17 | 33544313 | Regression of portal hypertension: underlying mechanisms and therapeutic strategies. | Hepatol Int | 2021 | https://conductscience.org/library/papers/33544313 | PubMed |
| 18 | 28734831 | Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. | Gastroenterology | 2017 | https://conductscience.org/library/papers/28734831 | PubMed |
| 19 | 39817915 | Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure. | Hepatology | 2025 | https://conductscience.org/library/papers/39817915 | PubMed |
| 20 | 17692984 | Grading and staging systems for inflammation and fibrosis in chronic liver diseases. | J Hepatol | 2007 | https://conductscience.org/library/papers/17692984 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41594255
GET https://conductscience.org/api/papers/v1/41594255/references?page=2